Clinical trial
A Phase 3 Randomized, Parallel Group, Double-Blind Study to Evaluate the Efficacy, Tolerability, and Safety of TR987® 0.1% Gel Versus Standard of Care in the Treatment of Chronic Venous Insufficiency Leg Ulcers (VLU)
NCT06707090 is registered in ClinicalTrials.gov with TR Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Randomized, Parallel Group, Double-Blind Study to Evaluate the Efficacy, Tolerability, and Safety of TR987® 0.1% Gel Versus Standard of Care in the Treatment of Chronic Venous Insufficiency Leg Ulcers (VLU)
- Lead sponsor
- TR Therapeutics
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- January 28, 2025
- Completion date
- February 29, 2028
- Enrollment
- 312 (estimated)
- Sites
- 33
Conditions
As the registry lists them; a condition with its own page is linked.
non-healing wound, venous insufficiency of leg, venous leg ulcer, venous stasis, venous stasis ulcer, venous ulcer, wound heal, wounds